Hyperkinesia and locomotor disorders have been reported with the prolonged use of the parent drug phenytoin, and further investigations are warranted to determine whether such effects may be due to the impairment of GTPCH1 activity by its metabolite phenytoin catechol. This evidence concerns the gene GCH1 and Hyperkinetic movements.